PFE - Bristol-Myers Squibb beats in Q4 as Eliquis and Opdivo outperform
2024-02-02 07:49:26 ET
More on Bristol-Myers Squibb
- Bristol-Myers Squibb: Don't Waver Over Undue Fears And Doubts
- Bristol Myers Squibb: Might Be Approaching A Bottom In 2024
- Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal
- Bristol-Myers Squibb beats top-line and bottom-line estimates; initiates FY24 outlook
- Earnings preview: Bristol Myers seen reporting lower Q4 earnings Friday